123 related articles for article (PubMed ID: 11912140)
1. Endogenous von Hippel-Lindau tumor suppressor protein regulates catecholaminergic phenotype in PC12 cells.
Bauer AL; Paulding WR; Striet JB; Schnell PO; Czyzyk-Krzeska MF
Cancer Res; 2002 Mar; 62(6):1682-7. PubMed ID: 11912140
[TBL] [Abstract][Full Text] [Related]
2. von Hippel-Lindau protein induces hypoxia-regulated arrest of tyrosine hydroxylase transcript elongation in pheochromocytoma cells.
Kroll SL; Paulding WR; Schnell PO; Barton MC; Conaway JW; Conaway RC; Czyzyk-Krzeska MF
J Biol Chem; 1999 Oct; 274(42):30109-14. PubMed ID: 10514498
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
4. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
[TBL] [Abstract][Full Text] [Related]
5. Regulation of tyrosine hydroxylase promoter activity by the von Hippel-Lindau tumor suppressor protein and hypoxia-inducible transcription factors.
Schnell PO; Ignacak ML; Bauer AL; Striet JB; Paulding WR; Czyzyk-Krzeska MF
J Neurochem; 2003 Apr; 85(2):483-91. PubMed ID: 12675925
[TBL] [Abstract][Full Text] [Related]
6. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
Siemeister G; Weindel K; Mohrs K; Barleon B; Martiny-Baron G; Marmé D
Cancer Res; 1996 May; 56(10):2299-301. PubMed ID: 8625303
[TBL] [Abstract][Full Text] [Related]
7. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
[TBL] [Abstract][Full Text] [Related]
8. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Blancher C; Moore JW; Robertson N; Harris AL
Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
[TBL] [Abstract][Full Text] [Related]
9. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
10. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.
Mukhopadhyay D; Knebelmann B; Cohen HT; Ananth S; Sukhatme VP
Mol Cell Biol; 1997 Sep; 17(9):5629-39. PubMed ID: 9271438
[TBL] [Abstract][Full Text] [Related]
11. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Marti HH; Plate KH
Blood; 1998 Nov; 92(9):3388-93. PubMed ID: 9787178
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
[TBL] [Abstract][Full Text] [Related]
13. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene.
Gnarra JR; Zhou S; Merrill MJ; Wagner JR; Krumm A; Papavassiliou E; Oldfield EH; Klausner RD; Linehan WM
Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10589-94. PubMed ID: 8855222
[TBL] [Abstract][Full Text] [Related]
14. Von Hippel-Lindau disease.
Sano T; Horiguchi H
Microsc Res Tech; 2003 Feb; 60(2):159-64. PubMed ID: 12539169
[TBL] [Abstract][Full Text] [Related]
15. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity.
Blankenship C; Naglich JG; Whaley JM; Seizinger B; Kley N
Oncogene; 1999 Feb; 18(8):1529-35. PubMed ID: 10102622
[TBL] [Abstract][Full Text] [Related]
16. von Hippel Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis.
Jones MK; Szabó IL; Kawanaka H; Husain SS; Tarnawski AS
FASEB J; 2002 Feb; 16(2):264-6. PubMed ID: 11772947
[TBL] [Abstract][Full Text] [Related]
17. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
Iliopoulos O; Levy AP; Jiang C; Kaelin WG; Goldberg MA
Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10595-9. PubMed ID: 8855223
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein.
Levy AP; Levy NS; Goldberg MA
J Biol Chem; 1996 Oct; 271(41):25492-7. PubMed ID: 8810320
[TBL] [Abstract][Full Text] [Related]
19. von Hippel-Lindau tumor suppressor protein represses platelet-derived growth factor B-chain gene expression via the Sp1 binding element in the proximal PDGF-B promoter.
Rafty LA; Khachigian LM
J Cell Biochem; 2002; 85(3):490-5. PubMed ID: 11967988
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma.
Igarashi H; Esumi M; Ishida H; Okada K
Cancer; 2002 Jul; 95(1):47-53. PubMed ID: 12115316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
